K********o
发帖数: 21 | 1 国内的朋友托我买BENLYSTA/belimumab。这是一种FDA今年3月才批准的新药，由Human
Genome Sciences 研制，可以治疗红斑狼疮。我在网上找不到购买该药的信息，去了
CVS，药剂师也不知道这种药，她建议我到医院去问问。我想请问，如何购买这种药，
或者，如何和医院联系。另外，用国内的处方（病历）可否在这里购买。多谢！ |
|
K********o
发帖数: 21 | 2 国内的朋友托我买BENLYSTA/belimumab。这是一种FDA今年3月才批准的新药，由Human
Genome Sciences 研制，可以治疗红斑狼疮。我在网上找不到购买该药的信息，去了
CVS，药剂师也不知道这种药，她建议我到医院去问问。我想请问，如何购买这种药，
或者，如何和医院联系。另外，用国内的处方（病历）可否在这里购买。多谢！ |
|
y*****l
发帖数: 5997 | 3 来自主题: _pennystock版 - HGSI bot 11. Target cut to 15 from 25.
http://seekingalpha.com/article/302210-today-s-weakness-in-huma
Human Genome Sciences Inc.'s (HGSI) September quarter report announced after
the close yesterday included sales figures for its lead BENLYSTA drug for
lupus that imply a slower ramp-up than is currently built into Wall Street
forward estimates. The company missed both revenue ($34 million versus $36.8
million) and earnings (45c loss versus 38c loss) estimates for the
September quarter.
Furthermore, ... 阅读全帖 |
|
y*****l
发帖数: 5997 | 4 来自主题: _pennystock版 - HGSI Human Genome Sciences Incorporated
Human Genome (HGSI) is scheduled to report earnings on Tuesday after the
close of the session. Human Genome has one approved drug, which is the
highly watched Benlysta. Briefly put, Benlysta was approved in March in
conjunction with GlaxoSmithKline (GSK). The treatment is priced at a
whopping $35,000 per year. Because of this, Human Genome's stock has lost
some of its luster because investors are not expecting large sales from the
treatment. This opens up an op... 阅读全帖 |
|
v**********m
发帖数: 5516 | 5 这下热闹了。
四家律师楼一起来。这种诉讼原告有赢的先例吗？
The Law Firm of Levi & Korsinsky Notifies Investors With Losses on Their
Investment in Human Genome Sciences, Inc. of Class Action Lawsuit and
the
Deadline of January 10, 2012 to Seek a Lead Plaintiff Position
NEW YORK, NY--(Marketwire - Nov 16, 2011) - Levi & Korsinsky announces
that
a class action lawsuit has been commenced in the District Court of
Maryland
on behalf of purchasers of Human Genome Sciences, Inc. ("HGS" or the "
Company") (NASDAQ: HGSI) common stock... 阅读全帖 |
|
y*****l
发帖数: 5997 | 6 11:55 Do you think there is > 50% chance someone buys HGSI in next 12 mos.?
Yes
( 68% )No
( 32% )
Thursday October 20, 2011 11:55
11:56 adam feuerstein: Hello! Welcome to the October edition of Biotech
Stock Live Chat.
Thursday October 20, 2011 11:56 adam feuerstein
12:02 adam feuerstein: hi everyone
Thursday October 20, 2011 12:02 adam feuerstein
12:02 adam feuerstein: I'll get started in a minute or so, let folks log in
.
Thursday October 20, 2011 12:02 adam feuerstein
12:02 adam feuers... 阅读全帖 |
|
y*****l
发帖数: 5997 | 7 来自主题: _pennystock版 - HGSI I think Amam clear the rumor and this is why hgsi dropped today."GSK buying
HGSI but only if Benlysta proves itself to be a significant commercial
success." I will bet ER.
Do you think there is > 50% chance someone buys HGSI in next 12 mos.?
Yes ( 68% )
No ( 32% )
12:09 [Comment From rt rt : ]
no comment, but we all knew the rumor of hgsi being bought was bogus, whats
your view?
Thursday October 20, 2011 12:09 rt
12:10 adam feuerstein: i tend to agree, mainly b/c rumors that get floated
lik... 阅读全帖 |
|
v**********m
发帖数: 5516 | 8 BENLYSTA 上市还不到一年，很多病人连一个疗程都还没有做完，销售怎么可能好呢。
大家好好等上一年吧，以现在的价格，我觉得100%的回报一定会有的。
在PEAK期这药有Billion 级别的销售额，而且Margin几乎是100%，比DNDN高不少。
Being Selective in Biotech: Carol Werther
Source: George S. Mack of The Life Sciences Report
News about The Life Sciences Report
March 2, 2012 (Investorideas.com Newswire) In an industry steeped in complex
research and speculative drug development, successful biotech investing
requires real sophistication. Senior Biotechnology Analyst Carol Werther of
Boston-based Summer... 阅读全帖 |
|
O**I
发帖数: 776 | 9 【 以下文字转载自 pennystock 俱乐部 】
发信人: OSCI (TX), 信区: pennystock
标 题: FDA Drug Approvals in 2011
发信站: BBS 未名空间站 (Sat Jan 8 17:29:50 2011, 美东)
http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
... 阅读全帖 |
|
O**I
发帖数: 776 | 10 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
O**I
发帖数: 776 | 11 http://www.thestreet.com/story/10944267/1/biotech-calendar-fda-
BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
More from Adam Feuerstein
Dendreon Bringing Provenge to EuropeBiotech Stock Mailbag: Best Stocks to
Watch in '11Merck Beats Vertex to FDA Hep C Filing
Market Activity
Orexigen Therapeutics Inc.| OREX
DOWN
Dendreon Corporation| DNDN
InterMune Inc.| ITMN
For easy reference, I've organized this regulatory ... 阅读全帖 |
|
w*******0
发帖数: 13 | 12 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
w*******0
发帖数: 13 | 13 BOSTON (TheStreet) -- An early Christmas present for biotech investors: The
first (overstuffed) FDA drug approval calendar of 2011.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regulatory milestones in 2011 based on
expected but not yet completed drug approval filings.
In all, this calendar ... 阅读全帖 |
|
y*****l
发帖数: 5997 | 14 http://www.thestreet.com/story/11016605/1/biotech-calendars-201
By Adam Feuerstein 02/22/11 - 07:36 AM ES
Stock quotes in this article:HGSI, OPTR, XNPT, SPPI, DRRX, PATH
BOSTON (TheStreet) -- I've updated the 2011 FDA drug approval calendar.
For easy reference, I've organized this regulatory calendar in chronological
order based on the drug approval decision date. I've also included
information on pending FDA advisory panels. At the end of the calendar is a
list of companies with potential regul... 阅读全帖 |
|
y*****l
发帖数: 5997 | 15 Date Company Name Ticker Drug Event Outcome Details
04/30/2011 GlaxoSmithKline PLC GSK, GSK.L Lamictal-XR (sNDA) FDA
decision on Lamictal-XR for conversion to monotherapy for treatment of
partial seizures FDA approved Lamictal XR for conversion to monotherapy
for treatment of partial seizures on Apr.25
-Drug Status
-Approved in Other Countries
04/29/2011 Spectrum Pharmaceuticals Inc SPPI Fusilev (sNDA) FDA
action on Fusilev for additional use in c... 阅读全帖 |
|
v**********m
发帖数: 5516 | 16 烟幕弹又来了，不知MM能拉到什么价位。
GlaxoSmithKline (GSK) And Biogen Idec (BIIB) Possible Candidates To Acquire
Human Genome Sciences (HGSI), Says Senior Analyst At Piper Jaffray; Read
More About This Prospect And Others In The Biotech Space In This Exclusive
Interview
November 21, 2011 - The Wall Street Transcript has just published
Biotechnology and Pharmaceuticals Report offering a timely review of the
Biotechnology sector. This Special Report contains expert industry
commentary through in-depth interviews w... 阅读全帖 |
|
g8
发帖数: 3784 | 17 The first new treatment for lupus in a half-century won U.S. approval on
Wednesday, a milestone for patients with the disabling disease and a
potential blockbuster for tiny biotech company Human Genome Sciences.
Health officials cleared Benlysta for certain patients with active lupus who
are receiving standard therapy. The disease causes the immune system to
attack joints and organs and has proved tough to study and treat.
Human Genome will split profits from the drug with GlaxoSmithKline.
In cl... 阅读全帖 |
|
b**a
发帖数: 1118 | 18 【 以下文字转载自 MoneyFriends 俱乐部 】
发信人: buaa (ming), 信区: MoneyFriends
标 题: A very reasonable post from Yahoo about HGSI
发信站: BBS 未名空间站 (Wed Apr 25 03:01:09 2012, 美东)
This is all about Darapladib. HGSI won't budge and should not until they
know the full potential of Darapladib. Shortie wants your stock because they
know where this is heading. GSK is not buying us for Benlysta at this point
. They are going to have to pay big time dollars to HGSI to get Darapladib
to market. Benlysta sales are growing,... 阅读全帖 |
|
a******e
发帖数: 1 | 19 http://en.wikipedia.org/wiki/Belimumab
Benlysta was approved by the U.S. Food and Drug Administration (FDA) for
treatment of SLE on March 9, 2011.
Belimumab (trade name Benlysta, previously known as LymphoStat-B)
or
Atacicept
Rituximab |
|
f**********g
发帖数: 2252 | 20 HGS and GlaxoSmithKline announce extension of PDUFA date for SLE drug
Monday 12/06/2010 9:47 AM ET - Datamonitor
Related Companies
Symbol Last %Chg
HGSI 25.95 1.37%
As of 10:18 AM ET 12/6/10
Human Genome Sciences, Inc., or HGS, and GlaxoSmithKline PLC have announced
that the FDA has extended the Prescription Drug User Fee Act, or PDUFA,
target date for its priority review of the Biologics License Application, or
BLA, for Benlysta as a potential treatment for systemic lupus erythematosus
from Dec... 阅读全帖 |
|
f**********g
发帖数: 2252 | 21 来自主题: _pennystock版 - HGSI Here is one more, Target $25
http://www.marketwatch.com/story/human-genome-jumps-11-on-takeo
BOSTON (MarketWatch) -- Shares of Human Genome Sciences /quotes/zigman/55662
/quotes/nls/hgsi HGSI +12.93% jumped 11% to $12.42 on Tuesday following a
report in the U.K.'s Daily Mail that GlaxoSmithKline PLC /quotes/zigman/
146635/quotes/nls/gsk GSK -0.23% could be preparing a bid of $25 a share for
the biotech group. Glaxo and HGSI, which have a long-standing research
collaboration, recently launched a ... 阅读全帖 |
|
w******9
发帖数: 1604 | 22 有人懂这个病吗？ 貌似是个难症。
好像这病是少女病，青蒿素真的有效？
-----
美国食品和药物管理局（Food and Drug Administration, 简称FDA）已经批准了Human
Genome Sciences Inc. 和葛兰素史克（Glaxosmithkline plc, GSK）的红斑狼疮新药
Benlysta上市，这是50多年来首次开发出红斑狼疮治疗新药。 |
|
发帖数: 1 | 23 Yarmouth Port, Massachusetts
From Wikipedia, the free encyclopedia
Yarmouth Port, Massachusetts
Census-designated place
Boardwalk at Bass Hole
Location in Barnstable County and the state ofMassachusetts.
Coordinates: 41°42′17″N 70°13′15″WCoordinates: 41°42′17″N 70°13′
15″W
Country United States
State Massachusetts
County Barnstable
Town Yarmouth
Area
• Total 6.47 sq mi (16.76 km2)
• Land 6.04 sq mi (15.65 km2)
• Water 0.43 sq mi (1.11 km2)
Elevation 52 f... 阅读全帖 |
|
发帖数: 1 | 24 在网上发现了一个圣诞节商店，商店的建筑很有特色，而且遍布全美国，大概有70多个
店铺，以后大家买圣诞节用品可以去那里，似乎各州都有。我们这里和麻州的地址是：
CHRISTMAS TREE SHOP AUGUSTA, GA, 239 ROBERT C. DANIEL JR. PARKWAY,
AUGUSTA EXCHANGE, AUGUSTA, GA 30909, 706.738.0570, CHRISTMAS TREE SHOP
, MAGNOLIA PARK, 1117 WOODRUFF ROAD, GREENVILLE, SC 29607. 864. 297.
3667
CHRISTMAS TREE SHOPS NATICK, 1298 WORCESTER ST. ROUTE 9, SHERWOOD
PLAZA, NATICK, MA 01760, 508.655.9800
CHRISTMAS TREE SHOPS SOMERVILLE, 177 MIDDLESEX AVENUE, ASSEMBLY SQUARE
... 阅读全帖 |
|
L****a
发帖数: 572 | 25 Lupus drug passes key test, researchers say
The experimental drug Benlysta greatly reduced symptoms of the life-
threatening autoimmune disorder, says Human Genome Sciences. The findings
offer hope that a 50-year drought in new drugs may end.
By Thomas H. Maugh II
3:09 PM PDT, July 20, 2009
After a 50-year drought of new drugs and a string of disappointing failures
of potential treatments for lupus, researchers said Monday they have found
an experimental drug that can ameliorate the symptoms of |
|
|
n****c
发帖数: 512 | 27 r u talking about this one?
FDA Sets Nov 16 Panel For Human Genome Sciences, Inc. (HGSI) And
GlaxoSmithKline (GSK) Lupus Drug; Benlysta Would be First New Lupus Drug in
50 Years |
|
J********e
发帖数: 341 | 28 Hepatitis C drug Zalbin first,
Benlysta is Dec 9.
in |
|
j*****7
发帖数: 4348 | 29 Zalbin的PDUFA是在十月四号， 没有人认为FDA会批； Benlysta的PDUFA是在十一月，
绝大多数人相信FDA会给过。
公司被收购的前景嘛， 我暂时不看好。 |
|
z*****8
发帖数: 132 | 30 “Human Genome Sciences And GlaxoSmithKline plc Announces FDA Extension of
BENLYSTA PDUFA Target Date To March 10, 2011”
完了。。。。 |
|
m*****t
发帖数: 1987 | 31 BTW, just searched a bit about lupus drugs and found this:
"A Food and Drug Administration advisory panel Tuesday voted 13-2 to
recommend approval of Benlysta, the
first new drug to treat lupus in more than half a century. "
It was posted Nov. 17, 2010 |
|
s******r
发帖数: 4749 | 32 这个情节是真的？
红斑狼疮都到了肾衰竭地步，已经非常严重了。
对了， 美国最近有一个治疗红斑狼疮的新药有可能会被FDA在今年3月批准，叫
Benlysta 。。。
来这就是永晨。
。永欣低垂了眼帘，不敢看她的眼睛。
扎一样疼，我就停薪留职了。”
裂红肿，还带着干枯的皮屑。她心里一阵发慌，安慰永晨说：“休息好了，养好身体，
没事儿做做志愿者也可以。”
，不知道是不是关节炎。”
套明星照吧。四千多块一套，妈嫌贵，只出一半，让我去找另外一半儿。”说完，有所
期待地看着永欣。
什么！”就没搭话。永晨等了一下，有些失望地说起了别的事儿。
她：“一天到晚不着家。”
觉得姐姐好好的没问题。但是一天夜里，永欣醒过来，听到细细的压抑的哭声。她仔细
听，却又没有了。 |
|
z****y
发帖数: 13 | 33 研究股票市场，发现一些小药厂一旦宣布新药Phase II或者Phase III通过，股价会在
很短时间内几倍几十倍的升，比如HGSI(Human Genome Sciences Inc.)从过去1年内股
价从$0.45 升到前不久的$32.07, 成长70多倍! 原因是HGSI有一个BENLYSTA新药通过了
Phase III，可以治systemic lupus，好象是治这个病的独门新药；
而CYCC(Cyclacel Pharmaceuticals, Inc.)在Jan 6收盘$1.06, Jan 8收盘已经达到$2.
96, 原因仅仅是由于有2篇文章发表，是利好消息，导致股价在3个交易日内上升接近2.
8倍!
恳请各位如果有什么哪家药厂的新药通过Phase III或者Phase II的消息，请不吝赐教
，大家一起积累财富，共同前进！
如果需要一起探讨，请发Email联系我，我的Email: z******[email protected],谢谢！ |
|
k******n
发帖数: 133 | 34 Well, I bought HGSI right before their Benlysta gets approved, and I still
hold it.That speaks my business sense.
However, I would join those two companies if given a chance. Big Pharm/
biotechs have the tendency to acquire those "platform" companies to keep
those techniques off the competitors' hands (Abgenix, CAT, Micromet, etc).
Sad for information sharing but good for business. |
|
k******n
发帖数: 133 | 35 Well, I bought HGSI right before their Benlysta gets approved, and I still
hold it.That speaks my business sense.
However, I would join those two companies if given a chance. Big Pharm/
biotechs have the tendency to acquire those "platform" companies to keep
those techniques off the competitors' hands (Abgenix, CAT, Micromet, etc).
Sad for information sharing but good for business. |
|
p****n
发帖数: 9263 | 36 这个，俺觉得没戏吧
CVS也许可以帮你订货，但是你得有米国医生开的处方才行，而这种注射抗体类药，就
算是常开违禁药的
野医没见过病人也不敢乱开啊。阿三也肯定还没山寨这种药呢
恐怕还得走正式途径，找国内医药公司从美国进口
Human |
|
y*****a
发帖数: 210 | 37 如果已经进入市场了，任何一个pharmacy 都可以帮你进的，但关键是要有美国医生的
处方，国外的处方在美国药房不会被接受的，不过如果有国内医生的处方，网上试试，
特别是加拿大的一些网站，经常听病人说从加拿大买药比美国便宜什么的，具体怎样操
作的就不清楚了 |
|
r********r
发帖数: 352 | 38 我刚考了law exam, 外国医生的处方，法律上，美国的pharmacy是可以给fill的（
control substance除外）。不过关键是除了法律允许之外，pharmacist还可以根据自
己的职业判断来决定是不是给你fill。如果是个cipro 之类的药，你解释一下原因，如
果合情合理，应该没有问题。可是癌症的药，我想换成我，我也不愿意但这个风险。所
以我觉得，过内的处方在这边买这个药几本没戏。 |
|
r***e
发帖数: 653 | 39 2月份，PLX (2/7), DDSS (2/11), CADX(2/12), XNPT (2/9), CTIC (2/10,Panel
Review), CRXX（2/22，估计要被据）
3月份: SUPG (3/8, 不是SUPG自己的), APPA (3/18,估计很玄)， SOMX (3/21, 三进宫了），MNTA (3/31)， STAA （3/31），
4月份：CYTX（4/7），CTIC(4/23，估计2月10结果就差不多出来了),POZN（4/30），
PLX: taliglucerase alfa for Gaucher's disease, FDA orphan drug and fast
track designation, 有pfizer的背书,临床结果好于竞争对手Genzyme的Cerezyme.三期
临床试验证明了安全和疗效,作为一个protein drug,只有6%的病人体内产生抗体.结果
不错.
DDSS:去年7月份悲剧是因为生产设施的问题,FDA没提疗效和安全的问题.这次是志在必
得.
CADX:IV acetaminophen (Acetavanc... 阅读全帖 |
|
g******0
发帖数: 1165 | 40 Posted: 3/13/10 09:32
I will list all these targets mentioned by news:
Their top five candidates, based on their takeout target rankings, include
Vertex Pharmaceuticals (VRTX), as the Massachusetts-based company is close
to commercializing telaprevir, a potential blockbuster treatment for
hepatitis C.
“The company is building a diversified portfolio,” says Migliore. “The
company has no drugs on the market, and it has never been profitable. But it
has an $8 billion market cap because investors ar... 阅读全帖 |
|
g******0
发帖数: 1165 | 41 发信人: gucci320 (Cigdog), 信区: pennystock
标 题: 转个老帖~潜在被收购的医药公司名单-（希望大家发现宝藏）
发信站: BBS 未名空间站 (Thu May 6 10:58:19 2010, 美东)
Posted: 3/13/10 09:32
I will list all these targets mentioned by news:
Their top five candidates, based on their takeout target rankings, include
Vertex Pharmaceuticals (VRTX), as the Massachusetts-based company is close
to commercializing telaprevir, a potential blockbuster treatment for
hepatitis C.
“The company is building a diversified portfolio,” says Migliore. “The
compan... 阅读全帖 |
|
B*****e
发帖数: 2413 | 42 All right $30~$35! Benlysta approvement is kind of priced in HGSI. |
|
B*****e
发帖数: 2413 | 43 All right $30~$35! Benlysta approvement is kind of priced in HGSI. |
|
j*****7
发帖数: 4348 | 44 １） HGSI： 销售慢慢的展开了， 政策面风险是唯一讨厌的事儿。各国政府都缺钱，
不情愿给报销。 不过美国， 加拿大， 欧盟都拿下来了， 也差不了哪里去。去患者论
坛上转了一圈， 基本上都是把Benlysta当神药的。关键是既吃不死人， 又治不好病，
只能减轻症状， 简直是B的好候选人。十月底出ER。
２） DSCO： 明年二月FDA决定日， 可能有pre-run， 这个大垃圾， 就算是过了也没
啥油水， 不过可能可以蒙散户。 |
|
f**********g
发帖数: 2252 | 45 来自主题: _pennystock版 - HGSI Piper Jaffrary Believes Now May Be Good Time for GSK to Acquire Human Genome
(GSK)
3 minutes ago - F70 via Comtex
Financial News Network Online - News CornerPiper Jaffray believes now be a
good time for GlaxoSmithKline (NYSE:GSK) to acquire Human Genome (NASDAQ:
HGSI) given the pullback in Human Genome shares.
Piper notes in addition to Benlysta, Human Genome and GSK collaborate on
Syncria for diabetes and darapladib for cardiovascular disease; two Phase
III assets Piper believes are not being v... 阅读全帖 |
|
B******o
发帖数: 565 | 46 来自主题: _pennystock版 - HGSI miss了吗，盘后下12了
BENLYSTA(R) U.S. gross sales $21.3 million; net sales $18.8 million |
|
v**********m
发帖数: 5516 | 47 来自主题: _pennystock版 - HGSI BENLYSTA sales increased gradually.
I do not see the missing ER has any impact in the long term. |
|
b*****h
发帖数: 783 | 48 看看现在HGSI benlysta的sale情况，3月份批的，批后的一个q卖了7.8M，再接下来一
个q 卖18.8
每个季度基本上都是80＋M 的loss，目前这种状况没法支撑1.5B cap.
卖药的趋势要看每个季度的报告，而且这种launch基调一定，很难突变。目前最多就是
短时超跌，反弹一点。。。我看要不是跌的实在是太便宜，还是不要贸然进入。。 |
|
